The nosology and treatment options for Cognitive Impairment in Parkinson Disease (PD) remains perhaps the greatest unmet clinical need.1 The reported frequency of mild cognitive impairment (MCI) in newly diagnosed PD has ranged from 22% to 43%.2,3 A proportion of those with PD-MCI progress to PD dementia (PDD), the prevalence of which is variously estimated between 24% and 31%,
The post Rethinking Cognition in Parkinson disease – Phosphodiesterase 4 appeared first on Palm Beach Neurological Center.
This post first appeared on News & Announcements Archives - Palm Beach Neurolo, please read the originial post: here